| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Case Reports; Journal Article
- Language: English
- [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 117-133. <i>Date of Electronic Publication: </i>2020 Oct 31.
- MeSH Terms: Disease Progression* ; Bone Marrow / *pathology ; Cell Transformation, Neoplastic / *pathology ; Education / *methods ; Myelodysplastic Syndromes / *pathology ; Myelodysplastic-Myeloproliferative Diseases / *pathology ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cell Transformation, Neoplastic / genetics ; Europe ; Female ; Germany ; Humans ; Male ; Middle Aged ; Myelodysplastic Syndromes / genetics ; Myelodysplastic-Myeloproliferative Diseases / genetics
- References: Hasserjian R P, Orazi A, Brunning R D et al (2017) Myelodysplastic syndromes: overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Revised, 4 th edn. IARC Press, Lyon, pp 98-106. ; Sperling AS, Gibson CJ, Ebert BL (2017) The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17:5–19. (PMID: 27834397) ; Malcovati L, Porta MG, Pascutto C et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594–7603. (PMID: 16186598) ; Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465. (PMID: 227404534425443) ; Bejar R, Stevenson K, Abdel-Wahab O et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496–2506. (PMID: 217146483159042) ; Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP (2017) Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 49:204–212. (PMID: 27992414) ; Shiozawa Y, Malcovati L, Gallì A, Pellagatti A, Karimi M, Sato-Otsubo A, Sato Y, Suzuki H, Yoshizato T, Yoshida K, Shiraishi Y, Chiba K, Makishima H, Boultwood J, Hellström-Lindberg E, Miyano S, Cazzola M, Ogawa S (2017) Gene expression and risk of leukemic transformation in myelodysplasia. Blood 2017(130):2642–2653. ; Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A, Solary E (2014) ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 28:2206–2212. (PMID: 24695057) ; Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, Oak J, Arber DA, Hsi E, Rogers HJ, Levinson K, Bagg A, Hassane DC, Hasserjian RP, Orazi A (2017) Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol 30:1213–1222. (PMID: 28548124) ; Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, de Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM (2019) Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica 104:1935–1949. (PMID: 310483536886439) ; Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A (2016) Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol 91:492–498. (PMID: 26874914) ; Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML (2015) The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet 47:1326–1333. (PMID: 264576474626387) ; Czader M, Orazi A (2015) Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms. Am J Clin Pathol 144:188–206. (PMID: 26185305) ; Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A, Steidl U (2019) Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med 25:103–110. (PMID: 30510255) ; Bejar R, Papaemmanuil E, Haferlach et al (2015) Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood 126:907. ; Nagata Y, Makishima H, Kerr CM, Przychodzen BP, Aly M, Goyal A, Awada H, Asad MF, Kuzmanovic T, Suzuki H, Yoshizato T, Yoshida K, Chiba K, Tanaka H, Shiraishi Y, Miyano S, Mukherjee S, LaFramboise T, Nazha A, Sekeres MA, Radivoyevitch T, Haferlach T, Ogawa S, Maciejewski JP (2019) Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat Commun 10:5386. (PMID: 317721636879617) ; Feurstein S, Thomay K, Hofmann W, Buesche G, Kreipe H, Thol F, Heuser M, Ganser A, Schlegelberger B, Göhring G (2018) Routes of clonal evolution into complex karyotypes in myelodysplastic syndrome patients with 5q deletion. Int J Mol Sci 19:3269. (PMID: 6214088) ; Cargo C, Bowen D (2017) Individual risk assessment in MDS in the era of genomic medicine. Semin Hematol 54:133–140. (PMID: 28958286) ; Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, Fulton R, Elliot K, Heath S, Grillot M, Westervelt P, Link DC, DiPersio JF, Mardis E, Ley TJ, Wilson RK, Graubert TA (2013) Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27:1275–1282. (PMID: 234434603736571) ; Stosch JM, Heumüller A, Niemöller C, Bleul S, Rothenberg-Thurley M, Riba J, Renz N, Szarc vel Szic K, Pfeifer D, Follo M, Pahl HL, Zimmermann S, Duyster J, Wehrle J, Lübbert M, Metzeler KH, Claus R, Becker H (2018) Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. Br J Haematol 182:830–842. (PMID: 29974943) ; Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, Kuo MC (2004) Acquisition of FLT3 or N-RAS mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18:466–475. (PMID: 14737077) ; Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G (2015) Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39:1367–1374. (PMID: 265472584822515) ; Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y, Ohyashiki JH (2005) The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19:2359–2360. (PMID: 16239910) ; Fu B, Jaso J, Sargent R et al (2014) Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol 27:681–689. (PMID: 24186132) ; Zhong B, Medeiros LJ, Wang W (2019) The emergence of a JAK2 V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis. Br J Haematol 186:396–396. (PMID: 31134612) ; Hussein K, Stucki-Koch A, Kreipe H (2018) Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis. Ann Hematol 97:2099–2106. (PMID: 29961094) ; de Renzis B, Mansat-De Mas V, Wattel E et al (2013) Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: a matched case control study. Leuk Res Rep 2:64–66. (PMID: 243717843850389) ; Chen C, Lin L, Tang J et al (2006) Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 20:1155–1158. (PMID: 16598312) ; Rigolin GM, Cuneo A, Roberti MG (1997) Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica 82:25–30. (PMID: 9107078) ; Wang SA, Galili N, Cerny J, Sechman E, Chen SS, Loew J, Liu Q, Oluwole F, Hasserjian R, Jones D, Qawi H, Woda B, Raza A (2006) Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol 126:789–797. (PMID: 17050076) ; Nagata Y, Zhao R, Awada H, Kerr CM, Goyal A, Mirzaev I, Kongkiatkamon S, Nazha A, Radivoyevitch T, Scott J, Sekeres MA, Hobbs BP, Maciejewski JP (2019) How morphologic features are shaped by underlying somatic genotype in MDS. Blood 134:1716. ; Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY, Chen CY, Tseng MH, Huang CF, Lai YJ, Chiang YC, Lee FY, Liu MC, Liu CW, Liu CY, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF (2014) Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J 4:e177. (PMID: 244422063913943) ; Campidelli C, Agostinelli C, Stitson R, Pileri SA (2009) Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol 132:426–437. (PMID: 19687319) ; Kaur V, Swami A, Alapat D, Abdallah AO, Motwani P, Hutchins LF, Jethava Y (2018) Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology 23:17–24. (PMID: 28574302) ; Pileri S, Ascani S, Cox M et al (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21:340–350. (PMID: 17170724) ; Li Z, Stölzel F, Onel K, Sukhanova M, Mirza MK, Yap KL, Borinets O, Larson RA, Stock W, Sasaki MM, Joseph L, Raca G (2015) Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia 29:2113–2116. (PMID: 257879144575593) ; Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, de Botton S (2018) Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia 32:2008–2081. (PMID: 29479068) ; Li H, Hasserjian RP, Kroft SH, Harrington AM, Wheaton SE, Pildain A, Ewalt MD, Gratzinger D, Hosking P, Olteanu H (2016) Pure erythroid leukemia and erythroblastic sarcoma evolving from chronic myeloid neoplasms. Am J Clin Pathol 145:538–551. (PMID: 2712494427124944) ; Visconte V, O Nakashima M, J Rogers H (2019) Mutations in splicing factor genes in myeloid malignancies: significance and impact on clinical features. Cancers (Basel) 11:1844. ; Lin CC, Hou HA, Chou WC, Kuo YY, Wu SJ, Liu CY, Chen CY, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Hsu SC, Ko BS, Tsay W, Chen YC, Tien HF (2014) SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution. Am J Hematol 89:E109–E115. (PMID: 24723457) ; Singh ZN, Post GR, Kiwan E, Maddox AM (2011) Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature. Clin Lymphoma Myeloma Leuk 11:293–297. (PMID: 21658659) ; Song J, Moscinski L, Zhang H, Zhang X, Hussaini M (2019) Does SF3B1/TET2 double mutation portend better or worse prognosis than isolated SF3B1 or TET2 mutation? Cancer Genomics Proteomics 16:91–98. (PMID: 305875036348401) ; Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP, Pardanani A, Tefferi A (2012) SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 26:1135–1137. (PMID: 22064353) ; Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP (2013) Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 26:751–761. (PMID: 23307061) ; Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable. Blood 132:2100–2103. (PMID: 302420876236463) ; Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T (2018) The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms. Haematologica 103:e192–e195. (PMID: 297001735927999) ; Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, Tefferi A (2015) ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol 90:653–656. (PMID: 25850813) ; Ammatuna E, Eefting M, van Lom et al (2015) Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ann Hematol 94:879-880. ; Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE (2016) Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7:14251–14258. (PMID: 268831024924712) ; Jung SI, Cho HS, Lee CH, Kim KD, Ha JO, Kim MK, Lee KH, Hyun MS (2008) Two cases of trisomy 19 as a sole chromosomal abnormality in myeloid disorders. Korean J Lab Med 28:174–178. (PMID: 18594167) ; Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A (2014) Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123:2645–2651. (PMID: 246275284067498) ; Vitte F, Fabiani B, Bénet C, Dalac S, Balme B, Delattre C, Vergier B, Beylot-Barry M, Vignon-Pennamen D, Ortonne N, Algros MP, Carlotti A, Samaleire D, Frouin E, Levy A, Laroche L, Theate I, Monnien F, Mugneret F, Petrella T (2012) Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations. A study of 42 cases. Am J Surg Pathol 36:1302–1316. (PMID: 22895265) ; Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L (2012) Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leuk Res 36:72–80. (PMID: 21782240) ; Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop M’K, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E (2019) Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 33:2466–2480. (PMID: 30894665) ; Zhang H, Wilmot B, Bottomly D, Dao KHT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW (2019) Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 134:867–879. (PMID: 313666216742922) ; Patnaik MM, Vallapureddy R, Lasho TL et al (2018) A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia 32:1850–1856. (PMID: 29712989) ; DeAngelo DJ, George TI, Linder A et al (2018) Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 32:470–478. (PMID: 28744009) ; Tanna S, Ustun C (2009) Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit? Int J Hematol 90:597–600. (PMID: 19760482) ; Tzankov A, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U, Hebeda KM (2018) Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 97:2117–2128. (PMID: 300840116182749) ; Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT (2017) Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol 44:1075–1079. (PMID: 28885734) ; Boiocchi L, Espinal-Witter R, Geyer JT, Steinhilber J, Bonzheim I, Knowles DM, Fend F, Orazi A (2013) Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol 26:204–212. (PMID: 23018876) ; Mori M, Matsushita A, Takiuchi Y, Arima H, Nagano S, Shimoji S, Kimura T, Inoue D, Tabata S, Yanagita S, Nagai K, Imai Y, Takahashi T (2010) Histiocytic sarcoma and underlying chronic myelomonocytic leukemia: a proposal for the developmental classification of histiocytic sarcoma. Int J Hematol 92:168–173. (PMID: 20535595) ; Arber DA, Brunning RD, Le Beau M et al (2017) Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Revised, 4th edn. IARC Press, Lyon, pp 130-149. ; Shanmugam V, Morgan EA, DeAngelo DJ, Kim AS (2019) Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. J Clin Pathol 72:93–96. (PMID: 30093508) ; Ansari J, Naqash AR, Munker R, el-Osta H, Master S, Cotelingam JD, Griffiths E, Greer AH, Yin H, Peddi P, Shackelford RE (2016) Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97:9–16. (PMID: 26990812) ; Russell L, Shaw NJ, Eden OB (1989) Hemophagocytosis and acute monoblastic leukemia. Pediatr Hematol Oncol 6:367–371. (PMID: 2641706) ; Unal S, Cetin M, Kutlay NY, Elmas SA, Gumruk F, Tukun A, Tuncer M, Gurgey A (2010) Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia. Ann Hematol 89:359–364. (PMID: 19798502) ; Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, la Rosée P, Kantarjian HM (2017) A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 123:3229–3240. (PMID: 286218005568927) ; Wang LX, Fei XM, Lu YL, Shi XF, Jiang Q, You HY, Ba R, Zhu Y (2010) Acute myeloid leukemia initially presenting as hemophagocytic lymphohistiocytosis - a case report and review of the literature. Leuk Res 34:e46–e49. (PMID: 19773082) ; Bodmer A, Menter T, Juskevicius D, Arranto C, Wenzel F, Dirnhofer S, Tzankov A (2017) Sharing of a PTPN11 mutation by myelodysplastic bone marrow and a mature plasmacytoid dendritic cell proliferation provides evidence for their common myelomonocytic origin. Virchows Arch 470:469–473. (PMID: 28116520) ; Orazi A, Chiu R, O'Malley DP, Czader M, Allen SL, An C, Vance GH (2006) Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol 19:1536–1545. (PMID: 17041567) ; Tzankov A, Hebeda K, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U (2017) Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 96:765–777. (PMID: 28191591) ; Vardiman JW, Melo JV, Baccarani M et al (2017) Chronic myeloid leukemia, BCR-ABL1-positive. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Revised, 4th edn. IARC Press, Lyon, pp 30-36. ; Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JL (2008) BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 112:5190–5192. (PMID: 188097622597614) ; Winter SS, Greene JM, McConnell TS, Willman CL (1999) Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone. Leukemia 13:2007–2011. (PMID: 10602422) ; Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, Schnittger S, Kern W, Müller MC, Hochhaus A, Haferlach T, Haferlach C (2011) A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25:557–560. (PMID: 21274004) ; Klumb CE, Barbosa TDC, Nestal de Moraes G et al (2019) IKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemia. Pediatr Blood Cancer 66:e27570. (PMID: 30511400) ; Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110–114. (PMID: 18408710) ; Menter T, Lundberg P, Wenzel F, Dirks J, Fernandez P, Friess D, Dirnhofer S, Tzankov A (2019) RUNX1 mutations can lead to aberrant expression of CD79a and PAX5 in acute myelogenous leukemias: a potential diagnostic pitfall. Pathobiology 86:162–166. (PMID: 30396184) ; Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, Liso A, Diverio D, Lo-Coco F, Falini B (2004) PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 64:7399–7404. (PMID: 15492262) ; Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J (2017) Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias (de novo and blast phase CML). Am J Hematol 92:E3–E4. (PMID: 27727470) ; Kim AS, Goldstein SC, Luger S, Van Deerlin VM, Bagg A (2008) Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib? Am J Clin Pathol 129:639–648. (PMID: 18343792) ; De Bie J, Demeyer S, Gielen O et al (2018) BCR-ABL1 positive B-ALL can undergo T-cell lineage shift to become CD19 negative T-ALL. Hemasphere 2:e42. (PMID: 317237706745988) ; Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M (2017) Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130:2027–2031. (PMID: 288274085726343) ; Zhang M, Lu J, Wang X, Cen J, Fan G, Hu S (2013) Early precursor T-lymphoblastic leukaemia/lymphoma arising from paediatric chronic myeloid leukaemia – unusual lymph node blast crisis. Br J Haematol 161:136–139. (PMID: 23278912) ; Guo ZP, Tan YH, Li JL, Xu ZF, Chen XH, Xu LR (2018) Acute pro-B-cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: a case report with literature review. Oncol Lett 15:9745–9750. (PMID: 298056855958712) ; Kouides PA, Bennett JM (1995) Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: case report and review of the literature of lymphoblastic transformation of myelodysplastic syndrome. Am J Hematol 49:157–162. (PMID: 7771469) ; Park TS, Song J, Lee KA, Lee SG, Yoon S, Kim JS, Lyu CJ, Choi JR (2007) der(1;15)(q10;q10) is a rare nonrandom whole-arm translocation in patients with acute lymphoblastic leukemia. Cancer Genet Cytogenet 179:132–135. (PMID: 18036400) ; Terada T (2012) TDT (-), KIT (+), CD34 (+), CD99 (+) precursor T lymphoblastic leukemia/lymphoma. Int J Clin Exp Pathol 5:167–170. (PMID: 22400079) ; Hu T, Murdaugh R, Nakada D (2017) Transcriptional and microenvironmental regulation of lineage ambiguity in leukemia. Front Oncol 7:268. (PMID: 291640655681738)
- Contributed Indexing: Keywords: Histiocytic transformation; Lymphoblastic; MDS; MDS/MPN; Mutations; Myeloid neoplasm; Progression; Transformation
- Entry Date(s): Date Created: 20201031 Date Completed: 20210113 Latest Revision: 20210113
- Update Code: 20240513
|
